Integrative proteogenomics and forward genetics reveals a novel mitotic vulnerability in triple-negative breast cancer

J Neill, Nicholas; Satpathy, S.; Krug, Karsten; K Meena, Jitendra; Ramesh Babu, Nivetha; Calderon, Cheyenne; Reed, Desmon; Weber, M.; Dobrolecki, L.; Lewis, Alaina; Sallas, C.; Anurag, M.; R Holloway, Kimberly; Huang, Chen; Vasaikar, S.; F Cardenas, Maria; Kim, Beom-Jun; W. Chan, Doug; C. Avanessian, Shayan; Tyagi, S.; Orellana, Mayra; Mao, Sufeng; Li, Heyuan; Gong, Fade; Kurley, S.; Meerbrey, K.; M Olson, Calla; Nair, Amritha; Sun, Tingting; Chung, Hsiang-Ching; A. Bowling, Elizabeth; H Wang, Jarey; Zhang, Pengju; Xiao, Peng; Yang, Duxiao; Stossi, F.; C. Polley, Mei-Yin; B. Saltzman, Alexander; Mundt, F.; Mani, D.; A. Gillette, Michael; Hilsenbeck, S.; Miles, George; Gutierrez, C.; Osborne, C.; Y. Lin, Charles; Gray, N.; Sun, Jin-peng; A. Wheeler, David; Perou, C.; Malovannaya, A.; T. Lewis, Michael; Zhang, Bing; J Ellis, Matthew; A. Carr, Steven; F Westbrook, Thomas

doi:10.1158/2159-8290.CD-23-1173

Public

Integrative proteogenomics and forward genetics reveals a novel mitotic vulnerability in triple-negative breast cancer

Shared by NobleBlocks on Aug 11, 2025 • 12:00 AM UTC

Authors:

Nicholas J Neill

S. Satpathy

Karsten Krug

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with few effective targeted therapies. Taxanes and other microtubule-targeting agents (MTAs) are frontline chemotherapies for TNBC; however, the molecular pathways that cause TNBC taxane sensitivity are largely unknown, p...

Subject

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!